S&P 500   3,304.73 (+0.72%)
DOW   27,223.28 (+0.28%)
QQQ   271.16 (+1.36%)
AAPL   110.61 (+0.48%)
MSFT   206.04 (+1.73%)
FB   252.77 (+1.86%)
GOOGL   1,450.25 (+1.41%)
AMZN   3,098.53 (+4.66%)
NVDA   499.00 (-0.34%)
TSLA   427.64 (-4.84%)
BABA   273.42 (-0.15%)
CGC   15.97 (+1.46%)
GE   6.22 (-2.05%)
MU   49.50 (+0.71%)
AMD   76.92 (-1.31%)
T   28.59 (-0.14%)
F   6.82 (-0.73%)
ACB   7.17 (+13.45%)
GILD   63.55 (-1.03%)
NFLX   488.40 (+0.22%)
DIS   126.85 (+1.15%)
BAC   23.87 (-2.45%)
BA   156.31 (-0.03%)
S&P 500   3,304.73 (+0.72%)
DOW   27,223.28 (+0.28%)
QQQ   271.16 (+1.36%)
AAPL   110.61 (+0.48%)
MSFT   206.04 (+1.73%)
FB   252.77 (+1.86%)
GOOGL   1,450.25 (+1.41%)
AMZN   3,098.53 (+4.66%)
NVDA   499.00 (-0.34%)
TSLA   427.64 (-4.84%)
BABA   273.42 (-0.15%)
CGC   15.97 (+1.46%)
GE   6.22 (-2.05%)
MU   49.50 (+0.71%)
AMD   76.92 (-1.31%)
T   28.59 (-0.14%)
F   6.82 (-0.73%)
ACB   7.17 (+13.45%)
GILD   63.55 (-1.03%)
NFLX   488.40 (+0.22%)
DIS   126.85 (+1.15%)
BAC   23.87 (-2.45%)
BA   156.31 (-0.03%)
S&P 500   3,304.73 (+0.72%)
DOW   27,223.28 (+0.28%)
QQQ   271.16 (+1.36%)
AAPL   110.61 (+0.48%)
MSFT   206.04 (+1.73%)
FB   252.77 (+1.86%)
GOOGL   1,450.25 (+1.41%)
AMZN   3,098.53 (+4.66%)
NVDA   499.00 (-0.34%)
TSLA   427.64 (-4.84%)
BABA   273.42 (-0.15%)
CGC   15.97 (+1.46%)
GE   6.22 (-2.05%)
MU   49.50 (+0.71%)
AMD   76.92 (-1.31%)
T   28.59 (-0.14%)
F   6.82 (-0.73%)
ACB   7.17 (+13.45%)
GILD   63.55 (-1.03%)
NFLX   488.40 (+0.22%)
DIS   126.85 (+1.15%)
BAC   23.87 (-2.45%)
BA   156.31 (-0.03%)
S&P 500   3,304.73 (+0.72%)
DOW   27,223.28 (+0.28%)
QQQ   271.16 (+1.36%)
AAPL   110.61 (+0.48%)
MSFT   206.04 (+1.73%)
FB   252.77 (+1.86%)
GOOGL   1,450.25 (+1.41%)
AMZN   3,098.53 (+4.66%)
NVDA   499.00 (-0.34%)
TSLA   427.64 (-4.84%)
BABA   273.42 (-0.15%)
CGC   15.97 (+1.46%)
GE   6.22 (-2.05%)
MU   49.50 (+0.71%)
AMD   76.92 (-1.31%)
T   28.59 (-0.14%)
F   6.82 (-0.73%)
ACB   7.17 (+13.45%)
GILD   63.55 (-1.03%)
NFLX   488.40 (+0.22%)
DIS   126.85 (+1.15%)
BAC   23.87 (-2.45%)
BA   156.31 (-0.03%)
Log in
NASDAQ:GRFS

GRIFOLS S A/S Stock Forecast, Price & News

$15.86
-0.02 (-0.13 %)
(As of 09/22/2020 02:34 PM ET)
Add
Compare
Today's Range
$15.71
Now: $15.86▼
$15.99
50-Day Range
$15.40
MA: $16.90▼
$19.08
52-Week Range
$13.40
Now: $15.86▼
$25.73
Volume17,919 shs
Average Volume1.15 million shs
Market Capitalization$10.90 billion
P/E Ratio17.62
Dividend Yield1.05%
Beta0.69
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Read More
GRIFOLS S A/S logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.23 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRFS
Previous Symbol
CUSIPN/A
CIK1438569
Webwww.grifols.com
Phone34-93-571-0000

Debt

Debt-to-Equity Ratio0.97
Current Ratio2.86
Quick Ratio1.18

Price-To-Earnings

Trailing P/E Ratio17.62
Forward P/E Ratio12.29
P/E Growth1.04

Sales & Book Value

Annual Sales$5.71 billion
Price / Sales1.91
Cash Flow$1.59 per share
Price / Cash Flow9.95
Book Value$11.15 per share
Price / Book1.42

Profitability

EPS (Most Recent Fiscal Year)$1.17
Net Income$700.16 million
Net Margins10.40%
Return on Equity10.83%
Return on Assets4.68%

Miscellaneous

Employees22,244
Outstanding Shares687,550,000
Market Cap$10.90 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$15.86
-0.02 (-0.13 %)
(As of 09/22/2020 02:34 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

How has GRIFOLS S A/S's stock been impacted by Coronavirus?

GRIFOLS S A/S's stock was trading at $20.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GRFS shares have decreased by 22.1% and is now trading at $15.86.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of GRIFOLS S A/S?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for GRIFOLS S A/S.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for GRIFOLS S A/S.

How were GRIFOLS S A/S's earnings last quarter?

GRIFOLS S A/S (NASDAQ:GRFS) announced its earnings results on Thursday, July, 30th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by $0.02. The biotechnology company earned $1.52 billion during the quarter, compared to analyst estimates of $1.46 billion. GRIFOLS S A/S had a net margin of 10.40% and a return on equity of 10.83%.
View GRIFOLS S A/S's earnings history.

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S announced a semi-annual dividend on Thursday, October 31st. Shareholders of record on Tuesday, December 3rd will be paid a dividend of $0.169 per share on Wednesday, December 11th. This represents a yield of 1.3%. The ex-dividend date of this dividend is Monday, December 2nd. This is an increase from GRIFOLS S A/S's previous semi-annual dividend of $0.15.
View GRIFOLS S A/S's dividend history.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

GRIFOLS S A/S's stock split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

Are investors shorting GRIFOLS S A/S?

GRIFOLS S A/S saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 2,180,000 shares, a drop of 11.4% from the August 15th total of 2,460,000 shares. Based on an average trading volume of 1,310,000 shares, the short-interest ratio is currently 1.7 days. Approximately 0.9% of the shares of the stock are sold short.
View GRIFOLS S A/S's Short Interest.

Who are some of GRIFOLS S A/S's key competitors?

Some companies that are related to GRIFOLS S A/S include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Genmab A/S (GMAB), Alexion Pharmaceuticals (ALXN), Beigene (BGNE), Shiseido (SSDOY), Genmab A/S (GNMSF), UCB (UCBJF), Merck KGaA (MKGAF), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), Catalent (CTLT) and BioMarin Pharmaceutical (BMRN).
View all competitors.

What other stocks do shareholders of GRIFOLS S A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR).

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the following people:
  • Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 55)
  • Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
  • Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)
  • Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
  • Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by many different institutional and retail investors. Top institutional investors include AKO Capital LLP (1.79%), FIL Ltd (1.72%), TPG Group Holdings SBS Advisors Inc. (0.76%), Black Creek Investment Management Inc. (0.48%), First Trust Advisors LP (0.45%) and Axiom International Investors LLC DE (0.32%).

Which institutional investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including AKO Capital LLP, Bank of America Corp DE, FIL Ltd, Marshall Wace LLP, Pelham Capital Ltd., CIBC Private Wealth Group LLC, Amia Capital LLP, and GABELLI & Co INVESTMENT ADVISERS INC..

Which institutional investors are buying GRIFOLS S A/S stock?

GRFS stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., First Trust Advisors LP, TPG Group Holdings SBS Advisors Inc., Sei Investments Co., UBS Group AG, Goldman Sachs Group Inc., Black Creek Investment Management Inc., and Kornitzer Capital Management Inc. KS.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $15.86.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $10.90 billion and generates $5.71 billion in revenue each year. The biotechnology company earns $700.16 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 22,244 workers across the globe.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is www.grifols.com.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-0000 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.